Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stakeholders Oppose Proposal To Cut IVIG Preadministration Fee In Medicare

Executive Summary

Industry groups are asking CMS to back off on a proposal to cut the $37 preadministration fee for intravenous immune globulin therapies administered in the hospital outpatient setting

You may also be interested in...



Plasma Group To Seek Legislation On IVIG Access As CMS Cuts Preadmin Fee

The Alliance for Plasma Therapies will begin working on convincing Congress that legislation is needed to ensure access to intravenous immune globulin therapies now that the preadministration fee in Medicare Part B has been dropped

Plasma Group To Seek Legislation On IVIG Access As CMS Cuts Preadmin Fee

The Alliance for Plasma Therapies will begin working on convincing Congress that legislation is needed to ensure access to intravenous immune globulin therapies now that the preadministration fee in Medicare Part B has been dropped

Increase In Pay For Part B Hospital Outpatient Drugs Needed, Groups Tell CMS

CMS' proposal to drop Medicare Part B drug reimbursement to average sales price plus 4 percent in the hospital outpatient setting is being met with calls for the agency to return to ASP plus 6 percent, the same rate physicians are reimbursed for drugs administered in their offices

Related Content

UsernamePublicRestriction

Register

PS050158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel